Timothy Coughlin, Director at Travere Therapeutics, Inc. (TVTX), sold 18,000 shares at $35.03 ($631K) on 2025-10-31, disclosed to the SEC on 2025-11-04.
Scheduled sale ($631k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| LIFE | BUY | 2024-06-03 | $88K | — | Filing → |
| FATE | SELL | 2022-06-06 | $33K | — | Filing → |